← Back to headlines
Citi Deems Daiichi Supply Review Immaterial for AstraZeneca
Citi analysts have concluded that the ongoing supply review concerning Daiichi is unlikely to have a significant impact on AstraZeneca's financial performance or operations.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
